.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX06_DinutuximabBeta.DinutuximabBeta .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX06_DinutuximabBeta.DinutuximabBeta| name: | DinutuximabBeta | |
| ATC code: | L01FX06 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 10 | mg |
| volume of distribution: | 2.5 | L |
| clearance: | 0.17 | L/h |
| other parameters in model implementation | ||
Dinutuximab beta is a monoclonal chimeric (mouse/human) antibody that targets the disialoganglioside GD2 antigen highly expressed on the surface of neuroblastoma cells. It is approved for use in Europe for the treatment of high-risk neuroblastoma in pediatric patients following induction chemotherapy and achieving at least partial remission.
Pharmacokinetic model as described in children with relapsed/refractory neuroblastoma; both sexes, pediatric age group. Parameters are based on published population PK model.